Javid Sara H, Kazerouni Anum S, Hippe Daniel S, Hirano Michael, Schnuck-Olapo Jamie, Biswas Debosmita, Bryant Mary Lynn, Li Isabella, Xiao Jennifer, Kim Andrew G, Guo Andy, Dontchos Brian, Kilgore Mark, Kim Janice, Partridge Savannah C, Rahbar Habib
Department of Surgery, University of Washington Medical Center, Seattle, WA, USA.
Department of Radiology, University of Washington, Seattle, WA, USA.
Ann Surg Oncol. 2025 May;32(5):3234-3243. doi: 10.1245/s10434-024-16837-x. Epub 2025 Jan 28.
Ductal carcinoma in situ (DCIS) is overtreated, in part because of inability to predict which DCIS cases diagnosed at core needle biopsy (CNB) will be upstaged at excision. This study aimed to determine whether quantitative magnetic resonance imaging (MRI) features can identify DCIS at risk of upstaging to invasive cancer.
This prospective observational clinical trial analyzed women with a diagnosis of DCIS on CNB. All the participants underwent preoperative 3T MRI. Quantitative MRI features from routine dynamic contrast-enhanced (DCE) MR images (e.g., peak percent enhancement [PE]) and from advanced high temporal-resolution DCE MR images (e.g., K) were measured. Clinical, pathologic, and mammographic features were reviewed. Associations with upstaging were summarized using the area under the receiver operating characteristic curve (AUC).
Of 58 DCIS lesions at CNB, 15 (26%) were upstaged to invasive cancer at surgery. Of the 58 lesions, 46 (79%) enhanced on MRI, although enhancement alone was not significantly associated with upstaging (p = 0.71). Among the DCIS lesions that enhanced, higher PE was most strongly associated with upstaging (AUC, 0.81; adjusted p = 0.009) and outperformed MRI features acquired via high temporal resolution DCE-MRI (AUC, 0.50-0.73). Lesion span on MRI was not significantly associated with upstaging risk (AUC, 0.55; adjusted p = 0.61), nor were any clinical, pathologic, or mammographic features (p > 0.24).
Quantitative features acquired from routine clinical breast MRI and advanced DCE-MRI demonstrated good performance in identifying which DCIS lesions were upstaged to invasive cancer at excision. These features may prove valuable for appropriate selection of active surveillance in future DCIS de-escalation trials.
导管原位癌(DCIS)存在过度治疗的情况,部分原因是无法预测在粗针活检(CNB)时诊断出的哪些DCIS病例在切除时会被升级分期。本研究旨在确定定量磁共振成像(MRI)特征是否能够识别有升级为浸润性癌风险的DCIS。
这项前瞻性观察性临床试验分析了经CNB诊断为DCIS的女性。所有参与者均接受了术前3T MRI检查。测量了常规动态对比增强(DCE)MR图像(如峰值增强百分比[PE])和高级高时间分辨率DCE MR图像(如K)的定量MRI特征。回顾了临床、病理和乳腺X线摄影特征。使用受试者操作特征曲线(AUC)下的面积总结与升级分期的相关性。
在CNB时的58个DCIS病变中,15个(26%)在手术时被升级为浸润性癌。在这58个病变中,46个(79%)在MRI上有强化,尽管单纯强化与升级分期无显著相关性(p = 0.71)。在有强化的DCIS病变中,较高的PE与升级分期相关性最强(AUC,0.81;校正p = 0.009),并且优于通过高时间分辨率DCE-MRI获得的MRI特征(AUC,0.50 - 0.73)。MRI上的病变范围与升级分期风险无显著相关性(AUC,0.55;校正p = 0.61),任何临床、病理或乳腺X线摄影特征也无相关性(p > 0.24)。
从常规临床乳腺MRI和高级DCE-MRI获得的定量特征在识别哪些DCIS病变在切除时被升级为浸润性癌方面表现良好。这些特征可能在未来DCIS降阶梯试验中对适当选择主动监测具有重要价值。